Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: ...

NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best multibagger penny stocks to invest in. On March 31, Recursion ...

Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer ...

Alphabet may be moving in the wrong direction this year, at least so far, but the company's multiple growth avenues (even ...

In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's real-world data and evidence into Recursion’s tech-enabled drug discovery and ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...